Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia
Neisha Sundaram, Cynthia Chen, Joanne Yoong, Munkh-Erdene Luvsan, Kimberley Fox, Amarzaya Sarankhuu, Sophie La Vincente, Mark Jit
Vaccine | ELSEVIER SCI LTD | Published : 2017
OBJECTIVE: The Ministry of Health (MOH), Mongolia, is considering introducing 13-valent pneumococcal conjugate vaccine (PCV13) in its national immunization programme to prevent the burden of disease caused by Streptococcus pneumoniae. This study evaluates the cost-effectiveness and budget impact of introducing PCV13 compared to no PCV vaccination in Mongolia. METHODS: The incremental cost-effectiveness ratio (ICER) of introducing PCV13 compared to no PCV vaccination was assessed using an age-stratified static multiple cohort model. The risk of various clinical presentations of pneumococcal disease (meningitis, pneumonia, non-meningitis non-pneumonia invasive pneumococcal disease and acute ot..View full abstract
We thank Mongolia's Ministry of Health for their support, advice and convening of experts to guide model development. We also especially thank Dr. D. Sodbayar (World Health Organization), Dr. D. Gantulga (NCCD), Ms. Narangav (NCCD), Mr. Shinebayar (NCCD), Dr G. Surenkhand (NCCD), Dr D. Narangerel (Public Health Unit and national EPI manager).This study was funded by the World Health Organization, Geneva and Gavi, the Vaccine Aliance. The WHO Regional Office for the Western Pacific provided travel support. The authors alone are responsible for the views expressed in this publication and they do not necessarily represent the decisions, policy or views of the World Health Organization. Nothing in this report should be construed as an endorsement by WHO or any other organization of any product.